<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - PAMIDRONATE DISODIUM</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>PAMIDRONATE DISODIUM</h1>

        <p><a href="../drugClass/PHP34620.html">BISPHOSPHONATES</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Hypercalcaemia of malignancy</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                15&#8211;60 mg, to be given (via cannula in a relatively large vein) as a single infusion or in divided doses over 2&#8211;4 days, dose adjusted according to serum calcium concentration; maximum 90 mg per course.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Osteolytic lesions and bone pain in bone metastases associated with breast cancer or multiple myeloma</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                90 mg every 4 weeks, to be administered via cannula in a relatively large vein, dose may alternatively be administered every 3 weeks, to coincide with chemotherapy in breast cancer.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Paget's disease of bone</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                30 mg every 1 week for a 6 week course (total dose 180 mg), alternatively initially 30 mg once weekly for 1 week, then increased to 60 mg every 2 weeks (max. per dose 60 mg) for a 6 week course (total dose 210 mg), to be administered via cannula in a relatively large vein, course may be repeated every 6 months; maximum 360 mg per course.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid&#8212;toxicity in <i>animal</i> studies.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Caution in severe hepatic impairment&#8212;no information available.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Max. infusion rate 20&#8239;mg/hour. Avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, except in life-threatening hypercalcaemia if benefit outweighs risk.</p><p>If renal function deteriorates in patients with bone metastases, withhold dose until serum creatinine returns to within 10% of baseline value.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, anaemia, anorexia, arthralgia, bone pain, constipation, diarrhoea, drowsiness, fever, headache, hypertension, hypomagnesaemia, hypophosphataemia, influenza- like symptoms (sometimes accompanied by malaise, rigors, fatigue and flushes), insomnia, lymphocytopenia, myalgia, nausea, paraesthesia, rash, symptomatic hypocalcaemia, tetany, thrombocytopenia, vomiting,
              </p>
              <p>
                <strong>rare:</strong> Acute renal failure, agitation, atypical femoral fractures, confusion, conjunctivitis, deterioration of renal disease, dizziness, dyspepsia, haematuria, hallucinations, hyperkalaemia, hypernatraemia, hypokalaemia, hypotension, isolated cases of seizures, lethargy, leucopenia, muscle cramps, osteonecrosis of the jaw, other ocular symptoms, pruritus,
              </p>
              <p>
                <strong>notKnown:</strong> Atrial fibrillation, injection-site reactions, reactivation of herpes simplex, reactivation of herpes zoster,
              </p>
        
        
            <section class="advice">
                <h3>Calcium and vitamin D supplements</h3>
              <p>Oral supplements are advised to minimise potential risk of hypocalcaemia for those with mainly lytic bone metastases or multiple myeloma at risk of calcium or vitamin D deficiency (e.g. through malabsorption or lack of exposure to sunlight) and in those with Paget&#8217;s disease.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>For <i>slow intravenous infusion</i> (<i>Aredia</i>
            <tm tmtype="reg"/>; <i>Pamidronate disodium</i>, Hospira, Medac, Wockhardt), give intermittently in Glucose 5% or Sodium chloride 0.9%; give at a rate not exceeding 1&#8239;mg/minute; not to be given with infusion fluids containing calcium.</p><p>For <i>Aredia</i>
            <tm tmtype="reg"/>, reconstitute initially with water for injections (15&#8239;mg in 5&#8239;mL, 30&#8239;mg or 90&#8239;mg in 10&#8239;mL), then dilute with infusion fluid to a concentration of not more than 90&#8239;mg in 250&#8239;mL.</p><p>For <i>Pamidronate disodium</i> (Wockhardt), dilute with infusion fluid to a concentration of not more than 60&#8239;mg in 250&#8239;mL <i>or</i> for <i>Pamidronate disodium</i> (Medac, Hospira) dilute with infusion fluid to a concentration of not more than 90&#8239;mg in 250&#8239;mL</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="patientResources">
              <p>A patient reminder card should be provided (risk of osteonecrosis of the jaw).</p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Atypical femoral fractures
          </li>
          <li>
            cardiac disease (especially in elderly)
          </li>
          <li>
            ensure adequate hydration
          </li>
          <li>
            previous thyroid surgery (risk of hypocalcaemia)
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor serum electrolytes, calcium and phosphate&#8212;possibility of convulsions due to electrolyte changes.</p><p>Assess renal function before each dose.</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of PAMIDRONATE DISODIUM</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP74968"><a href="../medicinalForm/PHP74968.html" data-target="#PHP74968" data-action="load">Solution for infusion</a></div>
            <div id="PHP74956"><a href="../medicinalForm/PHP74956.html" data-target="#PHP74956" data-action="load">Powder and solvent for solution for infusion</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
